The Evaluation and Management of Patients With Acute ChesT Pain in China

Acute Coronary Syndrome Clinical Trial

— EMPACT  

Official title:

The Evaluation and Management of Patients With Acute ChesT Pain in China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02536677
• Other study ID #: QLEmer201507
• Status: Completed
• Phase: N/A
• First received: August 27, 2015
• Last updated: January 6, 2018
• Start date: January 2016
• Est. completion date: October 2017

Study information

• Verified date: January 2018
• Source: Qilu Hospital of Shandong University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

EMPACT is the first attempt to comprehensively evaluate the current emergency care of acute chest pain from a regional representative sample in China.Findings will allow new opportunities to facilitate the clinical quality improvements and ultimately reduce the mortality and health care burden in patients with acute chest pain. It also will help to establish a regional network and database for further research and performance improvement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8374
• Est. completion date: October 2017
• Est. primary completion date: October 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Eighteen years and older

2. Presenting to the ED

3. With acute chest pain or suspected ACS

4. Symptoms occurring within 24 hours

5. Informed consent from patient or next of kin

Exclusion criteria

1. Chest pain caused by trauma

2. Persisting or recurrent chest pain caused by rheumatic diseases or cancer

3. Transferred from another grade II or grade III hospital

4. Presenting to the ED again within 30 days after initial enrollment

Related Conditions & MeSH terms

• Acute Chest Pain
• Acute Coronary Syndrome
• Chest Pain

Locations

Country	Name	City	State
China	Qilu Hospital of Shandong University	Jinan	Shandong

Sponsors (24)

Lead Sponsor

Collaborator

Yuguo Chen

Affiliated Hospital of Shandong Academy of Medical Sciences, Central Hospital of Zibo City, Jining Medical University, Linyi People's Hospital, People's Hospital of Chengwu, People's Hospital of Gaomi City, People's Hospital of Jinxiang County, People's Hospital of Longkou City, People's Hospital of Mudan, Heze City, People's Hospital of Shizhong District, Jinan City, People's Hospital of Shouguang City, People's Hospital of Wenshang County, Qianfoshan Hospital, Qilu Hospital of Shandong University, The 2nd People's Hospital of Dezhou City, The 2nd People's Hospital of Dongying City, The 2nd People's Hospital of Liaocheng City, The 2nd Traditional Chinese Medicine Hospital of Taian City, The 3rd People's Hospital of Jinan City, Traditional Chinese Medicine Hospital of Laoling City, Traditional Chinese Medicine Hospital of Pingyin County, Traditional Chinese Medicine Hospital of Wucheng County, Xinlongzhuang Colliery Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major adverse cardiac events (MACE)	The primary outcome was a composite of adjudicated MACEs, including death from all causes, non-fatal acute myocardial infarction (AMI), urgent revascularization, stroke, cardiac arrest, and cardiogenic shock.	30 days after presenting to the emergency departments(ED)
Secondary	revisiting to ED and rehospitalization		30 days after presenting to the EDs